Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis

We reported the association between interleukin 8 ( ) polymorphisms ( 251T/A and 781C/T) and hepatocellular carcinoma (HCC) risk in a meta-analysis. Scopus, PubMed, Web of Science, and Cochrane Library databases were searched until 21 November 2020. The analyses were performed by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (CIs). Also, the analysis of publication bias was performed by CMA 2.0 software. Searching databases/sources, five articles including ten studies were entered into the meta-analysis. The pooled ORs for polymorphism were 1.07 ( = 0.55), 1.04 ( = 0.75), 1.31 ( = 0.24), 1.24 ( = 0.31), and 1.85 ( = 0.29) for allele, homozygote, heterozygote, recessive and dominant models, respectively. With regards to polymorphism, the pooled ORs were 0.74 ( = 0.07), 0.53 ( = 0.03), 0.83 ( = 0.41), 0.75 ( = 0.19), and 0.57 ( = 0.02) for allele, homozygote, heterozygote, recessive, and dominant models, respectively. The findings of the meta-analysis showed a lack of significant association between (-251T/A) polymorphism and the HCC risk, whereas the TT genotype of (+781C/T) polymorphism had a protective role in HCC.